The discovery of imatinib (Gleevec), an inhibitor of tyrosine kinase activity of BCR/ABL, was a breakthrough in the treatment of chronic myeloid leukemia (CML). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.